Scroll Top
Emerging Markets Report
Mindset Pharma logo

Mindset Pharma Inc.


More Tools in the Toolbox | 04/22/2022 |

Sometimes as we continue our coverage of Mindset Pharma Inc. (Mindset) (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) it feels as if we are covering TWO unique stories.

And maybe we are.

As you may recall, Mindset is a drug discovery and development company focused on creating next-generation psychedelic medicines to treat neurological and psychiatric disorders. Most of what we cover about Mindset are the Company’s advancements in drug development that assist them in their perpetual goal of helping patients have better outcomes using psychedelics.

But perhaps the larger, parallel story is that this psychedelics-as-medicine paradigms seems to be at a point that real treatments are emerging and doctors and companies are learning from these early treatments.

This article from Harvard Health Publishing talks both about how far psychedelics have come … and how far they might go.

And this article from the venerable New York Times leads with the bold headline, “The Psychedelic Revolution is Coming. Psychiatry May Never Be the Same.”

Image of Molecule

That’s why the recent news from psychedelic pioneers Mindset Pharma is incredibly important. In the release, Mindset announces the filing of a new provisional patent application that covers new chemical entities (NCEs) that expand the Company’s next-generation DMT and 5-MeO-DMT, or ‘Family 4’, platform, currently under development.

This new patent application exemplifies the Mindset corporate strategy to broaden the therapeutic psychedelic toolbox for patients with mental health disorders who are waiting for transformative medicines and covers novel chemical space while maintaining the functionality of traditional psychedelics

Image of Psychedelic Mushrooms in Lab

A quote from CEO James Lanthier explains the significance of the filing:
“As we get more human clinical data from first generation psychedelic drugs, we will unravel how different patients respond to different psychedelic therapies. Our expectation is that different patients will respond to different treatments and paradigms. In an effort to build a toolbox that helps the most patients, Mindset continues to build out its patent portfolio.”

And that’s the part we think is compelling, even resonant. Mindset is growing in a growth industry, developing more options as acceptance broadens and the earth moves under its proverbial feet. Remember when Washington and Colorado were rebels, bold early adopters that were the first states to legalize recreational cannabis use? Now, we’re talking about the possible end to federal prohibition as a vast amount of states allow recreational and medical use.

We may be at a similar precipice, a tipping point. Those articles from The New York Times and Harvard are from last year. Since that time Mindset has put more tools in the toolbox.

And let’s not kid ourselves. Mindset is a public company and as much as the narrative is and should be about the potentially transformative effects of psychedelic treatments, the story may someday be about a Company who has generated intellectual property with potential revenue streams that could be valuable in a fully exploited psychedelic health care market.

It wasn’t that long ago that Oregon was the first to legalize psychedelic mushrooms, a move that if similar to the seminal decriminalization of cannabis in Washington and Colorado a decade ago, could lead a very large psychedelic treatment market sooner than later.

If that happens, Mindset is already well down the road of putting tools in the toolbox.

About The Emerging Markets Report:
The Emerging Markets Report is owned and operated by Emerging Markets Consulting (“EMC”), a syndicate of investor relations consultants representing years of experience. Our network consists of stockbrokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

Must Read OTC Markets/SEC policy on stock promotion and investor protection

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.


EMC has been paid $250,000 by Mindset Pharma, Inc. for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. | Please read our full disclaimer.

Subscribe to our newsletter for must read alerts.

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.